|Bid||81.68 x 900|
|Ask||84.98 x 1800|
|Day's range||81.67 - 85.75|
|52-week range||78.85 - 120.54|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||22.59|
|Earnings date||03 Aug 2022 - 10 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||137.57|
It hasn't been the best quarter for Horizon Therapeutics Public Limited Company ( NASDAQ:HZNP ) shareholders, since the...
DUBLIN, June 24, 2022--New analysis finds UPLIZNA (inebilizumab) effective among European populations with neuromyelitis optica spectrum disorder (NMOSD).
DUBLIN, June 15, 2022--Horizon Therapeutics has submitted a regulatory filing for UPLIZNA® in Brazil for NMOSD.